PK-101-002

PK-101-002 is a small molecule drug developed by Pionex Management Group Pharm (PMG Pharm) as part of a combination therapy for osteoarthritis, particularly knee osteoarthritis. It is an oral agent and has been studied both alone and in combination with PK101-001, forming the fixed-dose product known as PK 101. The primary therapeutic area is musculoskeletal diseases, specifically arthritis and osteoarthritis. While the precise mechanism of action for PK-101-002 itself has not been explicitly defined in public sources, the broader combination product (PK 101) is described as a nonsteroidal anti-inflammatory analgesic (NSAID) with increased effectiveness and reduced cardiovascular and gastrointestinal side effects compared to traditional NSAIDs. Clinical development has reached Phase 3 trials in South Korea for knee osteoarthritis[1][4][7][8].